Chimeric Therapeutics (ASX:CHM) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Chimeric Therapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Chimeric Therapeutics's average Total Assets over the quarter that ended in Dec. 2023 was A$24.53 Mil. Therefore, Chimeric Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Chimeric Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Chimeric Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Gross-Profit-to-Asset % Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Chimeric Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Chimeric Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Gross-Profit-to-Asset % falls into.

Chimeric Therapeutics Gross-Profit-to-Asset % Calculation

Chimeric Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0	/	( (34.88	+	22.376)	/ 2 )
	=	0	/	28.628
	=	0.00 %

Chimeric Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (22.376	+	26.688)	/ 2 )
	=	0	/	24.532
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Chimeric Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines